New antibody MTX-439 enters first human trial for diabetic kidney disease
NCT ID NCT07473323
First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This early-stage trial tests a new drug called MTX-439, an antibody that blocks a protein linked to kidney scarring. It will be given to healthy volunteers and people with diabetic kidney disease to check for safety and how the body processes it. The study is small (88 participants) and aims to find a safe dose for future testing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MTX-439 (an antibody that targets a protein called SMOC2)
What this could lead to
If successful, this could point toward a new treatment option for diabetic kidney disease by targeting a protein involved in scarring.
What could go wrong
This is a very early Phase 1 trial focused on safety, not effectiveness. It is small (88 people) and may not lead to a working treatment. Side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Doherty Clinical Trials
RECRUITINGMelbourne, Victoria, 3002, Australia
Contact Phone: •••-•••-••••